OBJECTIVES: The objective of this study was to evaluate the effect of an intra-aortic filter on postoperative outcomes in high-risk cardiac surgical patients.
INTRODUCTION
Manipulation of the heart and atheromatous aorta during cardiac surgery contributes to distal embolization, which plays a significant role in postoperative complications. In high-risk patients with a severely diseased ascending aorta with aortic calcification, cross-clamping of the aorta can cause stroke in up to 19% of patients [1] . Other atheroembolic migrations during cardiac surgery were also documented in the spleen (10.9%), kidney (10.4), pancreas (6.8%), gastrointestinal tract (4.5%) and liver (3.0%) [2] . All of these events can significantly add to postoperative complications, prolong postoperative intensive care unit (ICU) and hospital stays, and increase the mortality rate. The EMBOL-X Glide Protection System (Edwards Life Sciences, Irvine, CA, USA) is an aortic filter designed to capture the emboli released proximally during aortic and cardiac manipulation. The filter is deployed through a specially designed aortic cannula with an integrated port to eliminate the need for a second aortotomy.
When the EMBOL-X filter was deployed, emboli were found in 97-100% of the filters without any complications attributed to the use of the filter, rendering the filter both effective in capturing particulates and safe [3] [4] [5] . Yet, whether the capture of particulate emboli has clinical relevance is still under debate.
The current retrospective study was undertaken to evaluate the effectiveness of the EMBOL-X filtration device by comparing morbidity and mortality rates and other relative factors in high-risk cardiac surgical patients. The two groups were the filtration group-those highrisk patients with the EMBOL-X filter-and the control group-those patients without the EMBOL-X filter.
METHODS
The study was carried out with the approval of our institutional review board. The data used for this project were obtained from An intra-aortic filter was used in 316 (4.9%) high-risk patients of 6442 cardiac cases performed at a single institution from 2003 to 2013. The decision to use the intra-aortic filter was made by a surgeon based on assessment of the preoperative and intraoperative factors. Routine preoperative calculation of the STS mortality score guided this decision-patients with high STS scores (≥4%) were strongly considered for the EMBOL-X. Other important factors included the routine assessment of aortic calcifications by preoperative computed tomographic (CT) scans of the chest, and intraoperative transoesophageal echocardiography, palpation of the aorta and the use of epiaortic ultrasound.
The registry data that were extracted included preoperative demographic data (age, race and prior cardiac operations); preoperative risk factors (surgical priority, ejection fraction, extent of coronary artery disease, kidney function, extent of cardiac vessel/valve disease, previous myocardial infarction and other medical comorbidities such as diabetes, renal insufficiency and hepatic failure) and intraoperative variables (length and type of surgery, use of β-blockers, intraoperative haematocrit, time to extubation and number of transfusions). The end-points examined were 30-day mortality rate, stroke, transient ischaemic attack, renal insufficiency/failure, myocardial infarction, gastrointestinal complications, limb-threatening ischaemia, sternal infection, respiratory failure, reoperation, length of stay (LOS) and a composite of these events.
Statistical methods
Assuming a 15% rate of overall complications in the sample, we hypothesized that use of the EMBOL-X would decrease that number by half or to 7.5%. A power calculation estimated that a sample of 184 EMBOL-X patients matched to four controls each would provide at least 80% power to test the hypothesized difference with an α = 0.05. Given the large number of control patients, the decision was made to match the EMBOL-X patients at a ratio of 1 to 6.
Continuous variables were tested for normality using the Shapiro-Wilk test. Normally distributed variables were described in terms of mean ± standard deviation; skewed variables, in terms of median (interquartile range); and categorical variables, in terms of frequency (per cent). Propensity scores [6] were estimated using logistic regression to predict group membership (EMBOL-X versus non-EMBOL-X) based on STS mortality score and type of surgical procedure [i.e. coronary artery bypass grafting (CABG), valve replacement or both]. The STS mortality score is an extensively used estimate of the patients' risk for death and other surgically related morbidities, whereas the type of procedure was included to control for risks inherent in each type of procedure. The resulting probability scores from the logistic regression were then utilized as propensity scores to match the EMBOL-X patients with non-EMBOL-X patients. The Hosmer-Lemeshow χ 2 goodness-of-fit test was used to test the adequacy of the propensity score matching model. The 1 to n matching (e.g. n = 6) was done using the SAS macro OneToManyMTCH [7] , which employs a 'greedy' algorithm, whereby a set of X EMBOL-X patients was matched to a set of Y (i.e. where Y = n × X) non-EMBOL-X patients; once a non-EMBOL-X patient was matched to an EMBOL-X patient, that match was not re-evaluated or changed. Each EMBOL-X patient was first matched to his or her 'best' non-EMBOL-X patient on the basis of the first eight digits of their propensity scores. The EMBOL-X patient was then matched to non-EMBOL-X patients based on 'next best' matches (based on the first seven digits, then first six digits and so forth). If an EMBOL-X patient could not be matched with 6 non-EMBOL-X patients, she was removed from the set of matches at the time she failed to receive a matched control. The corresponding non-EMBOL-X patients were also removed from the set of matches and added back to the pool of unmatched controls to be possibly matched to another EMBOL-X patient. The unmatched EMBOL-X patients were compared descriptively with the matched EMBOL-X patients due to the small numbers of unmatched subjects. Adequacy of the matching was also evaluated by comparing the EMBOL-X patients with the non-EMBOL-X patients with regard to the STS mortality score and the type of procedure.
Variables such as patient characteristics (age, gender and presurgical hypertension) and surgical outcomes (complication rates and LOS) were compared using generalized linear modelling. This procedure allowed us to account for the correlation between the matched EMBOL-X and non-EMBOL-X samples and carry out paired group comparisons. An underlying normal distribution was assumed for normally distributed variables (e.g. age); an underlying gamma distribution was assumed for skewed variables (e.g. LOS), while an underlying binary distribution was assumed for yes/no outcomes (e.g. respiratory failure).
Interaction tests were added to the basic generalized linear model to look at the influence in EMBOL-X patients of complications on LOS and total ICU time as well as to test for differences due to the procedure. Demographic or clinical characteristics that showed significance were added as covariates to the generalized linear model to control for possible confounding. The propensity score matching and all statistical tests were carried out using SAS 9.4 (SAS Inc., Cary, NC, USA. No correction for the number of comparisons was done; all tests used a level of significance of <0.05).
RESULTS
A retrospective analysis of the 6442 patients in the STS registry from a single institution identified 6430 patients with no prior cardiac surgery; 6347 patients without shock or haemodynamic instability; 5531 with CABG (n = 3895), isolated valve replacement (n = 1009) or combined CABG and valve replacement (n = 647) as procedures; and 4822 with a valid STS mortality score. Accounting for all of the exclusion and inclusion criteria resulted in a final data pool of 4712 patients, 209 of whom received the EMBOL-X intra-aortic filter and 4503 who did not. The EMBOL-X patients were then matched to the control patients using the propensity score method described above.
Overall, before matching, the EMBOL-X patients (n = 316) had a significantly higher risk of mortality than the non-filter patients: 12.0% of filter patients had an STS mortality risk score ≥4 vs 7.7% of non-filter patients (P = 0.027).
When it was applied to the 209 EMBOL-X and 4503 non-EMBOL-X patients who met the inclusion/exclusion criteria, the Hosmer-Lemeshow goodness-of-fit test for logistic regression was not significant and showed a good fit for the model: χ 2 test = 7.842, df = 8, P = 0.45. On the basis of the propensity score matching program, 204 (98% of 209 patients) EMBOL-X patients were successfully matched with 1224 non-EMBOL-X patients; 5 EMBOL-X patients out of 209 (2.4%) could not be matched. Using a 1:4 matching ratio resulted in the same number of EMBOL-X patients being matched. The unmatched patients were exclusively combined CABG and valve replacement patients with very high STS mortality scores (median for unmatched patients was 18.59 [IQR 16.49-22.41]). Due to the small number of unmatched cases, no further comparisons were done between the matched and unmatched EMBOL-X patients.
The matched patients had the following procedures: 89 CABGs (44%); 63 (31%) valve replacements and 52 (25%) CABG/valves. The difference in median risk scores for the matched groups was not statistically significant (P = 0.14). Likewise, there was no significant difference in the distribution of patients receiving the different types of procedures (P = 0.79). Table 1 presents the basic demographic and clinical characteristics of the EMBOL-X and control patients. The mean age of the EMBOL-X patients was 67 vs 66 years for the control patients (P = 0.09). Women made up 36% of the EMBOL-X group versus 34% of the control group. The mean body mass index was 29.5 in the EMBOL-X group and 28.9 in the control group (P = 0.11). EMBOL-X patients were significantly less likely to be hypertensive (72 vs 83%; P < 0.001). None of the other clinical characteristics that were examined showed any statistically significant differences between the EMBOL-X patients and the control patients, although EMBOL-X patients showed a higher rate of diabetes [34 vs 28%, respectively (P = 0.06)].
A comparison of the differences in clinical outcomes between the groups is given in Table 2 . The EMBOL-X group had a significantly lower complication rate than the control group (6.8 vs 13.2%; P = 0.02). The only specific outcome that showed a significant difference between the groups was respiratory failure, with a 2.5% rate for the EMBOL-X group and a 7.0% rate for the control group (P = 0.02). These significant differences remained even after controlling for hypertension, indicating that the significant differences in complications were not due to possible confounding. Comparing the EMBOL-X group versus the control group also showed lower but not significantly different rates of gastrointestinal bleeding (1.4 vs 1.9%; P = 0.73) and renal failure (1.0 vs 2.5%; P = 0.22). The mortality rate was also lower, but it was not significantly different in the EMBOL-X group (2.5vs 3.0%, P = 0.71). No statistical tests were possible for stroke or transmyocardial infarction due to the low rate of occurrence. LOS for each group as a whole was virtually identical across the filter and control groups (median = 7 days for both groups; P = 0.75). Similarly, the median total time in the ICU was not significantly different for the EMBOL-X versus the control patients (60 vs 71 h; P = 0.67). However, a difference in total time in the ICU became evident when the relationship between time in the ICU and the number of complications in each group was analysed. The total ICU time for EMBOL-X patients with complications was 163 vs 189 h for comparable control patients (P = 0.02 for the group × complication interaction). Again, after controlling for any possible confounding associated with race and hypertension, the total ICU time was still significantly lower for EMBOL-X patients with complications versus control patients with complications.
The differences in complication rates between the EMBOL-X and control groups also tended to be consistent across procedure types; the test result for interaction between procedure type and EMBOL-X filter was not significant (0.64). The odds ratio for the overall complication rate was 1.98. Comparing the odds ratios between the EMBOL-X and control groups across procedure types supported this observation. Valve patients who got the EMBOL-X had an overall complication rate of 3.00 vs 8.00% for the control patients (OR = 2.81 for valve patients). For CABG EMBOL-X patients, the overall complication rate was 8.00 vs 13.00% for the controls (OR = 1.72 for CABG). Finally, for combined valvereplacement and CABG patients, the EMBOL-X group had an overall complication rate of 12.00%, whereas it was 21.00% for the control patients (OR = 1.95 for combined procedure patients).
DISCUSSION
Despite the use of EMBOL-X since 1999, only a limited amount of data has been published relative to the efficacy of the filter in reducing the rate of complications due to embolic events. In a multi-institutional, randomized trial with an enrolment of 1289 patients, Banbury and colleagues [8] were unable to show any differences in mortality rate, stroke, transient ischaemic attacks (TIAs), renal insufficiency, Q-wave myocardial infarction, elevated levels of CK-MB, all myocardial infarctions and all composite events when patients with an aortic filter were compared with controls. However, in their post hoc analysis, which is fraught with limitations, patients with aortic filters with moderate to high preoperative risk (Higgins >5) were shown to have a statistically significant reduction in renal insufficiency and in the composite end-points. In our study, the EMBOL-X filter was only used in patients with high STS mortality risk scores. Overall, before matching, EMBOL-X patients (n = 316) had a significantly higher risk of death than the non-filter patients: 12.0% of filter patients had an STS mortality risk score ≥4 vs 7.7% of non-filter patients (P = 0.027).
However, after these higher-risk patients were matched with non-filter patients by the STS mortality score, EMBOL X patients had significantly lower overall complication rates compared with the control group (7 vs 13%; P = 0.02). Major complications included stroke, myocardial infarction, sternal infection, preoperative bleeding, sepsis, all gastrointestinal bleeding, renal failure and respiratory failure. Thus, the present study confirmed the findings of Banbury and colleagues [8] , which were derived from a post hoc analysis.
Analysis of individual complications in the present study revealed only respiratory failure (defined by intubation >72 h) to be significantly decreased, with a rate of 2.5% for the EMBOL-X group and 7% for the control group (P = 0.02). Presumably, prevention of systemic microembolization in the EMBOL-X group could decrease the incidence of acute lung injury and respiratory failure. But a more clinically relevant explanation can be drawn from the fact that any major complication can cause delays in early extubation. The fact that the rate of respiratory failure in the EMBOL-X group in this study was directly related to the rate of major complications makes these findings clinically meaningful.
Other studies have, however, shown a benefit for individual complications. In a study by Schmitz et al. [9] , 582 patients (304 of whom had intra-aortic filtration) were examined for neurological outcomes after cardiac surgery. The findings were significant for reduction in TIAs (0 vs 1.4%), delirium (3.0 vs 6.5%) and memory deficit (1.3 vs 6.2%) in the filter group compared with the control group. Overall, the incidence of neurological deficits was lower in the experimental group (4.3 vs 11.9%. P = 001). The authors, however, admit that the study is limited by the non-randomization of patients and the small number of neurological complications. Because only 46 (less than 10%) adverse neurological events were seen in 582 patients, the data must be interpreted with caution. Wimmer-Greinecker et al. [10] looked at the use of an intra-aortic filter for CABG, valve surgery or both in 458 patients (185 with intra-aortic filtration) and found a statistically significant reduction in non-fatal stroke (0.5 vs 5.9%) and total Type I outcome defined as stroke, TIA, coma and death due to neurological causes (2.2 vs 8.4%). The study was also limited by non-randomization of the patients, comparison of the filter data collected from 1999 to 2001 where the data for the controls were collected from 1991 to 1993 and inclusion of both American and European data, which may carry technical and procedural differences.
In the present study, no strokes occurred in the filter group. Although we believe that intra-aortic filtration can effectively reduce the rate of mortality and of other major complications, the sample size in the present study could only show the trend in such categories. Rates of strokes (0 vs 0.7%, P = NA), new-onset postoperative haemodialysis (1.0 vs 2.5%, P = 0.22) and mortality (2.5 vs 3.00%, P = 0.71) were not statistically significant, although the rates of strokes and new-onset haemodialysis were almost 50% less in filter patients. Contemporary rates of complications after CABG, isolated valve and CABG/valve operations are low, and it is difficult to have enough study power to show a statistically significant difference for each complication. There were no differences in mean risk factors between the EMBOL-X and control after matching participants. There were no statistically significant demographic differences, except in the use of EMBOL-X in the different races. LOS in the ICU for patients with complications was significantly shorter for the patients receiving the EMBOL-X (163 vs 189 h, P = 0.008). This may be due to a reduction in the severity of the complications due to the fact that a majority of particulate emboli and larger emboli were captured by the filter. Therefore, the complications that do occur are less serious and resolve faster, decreasing LOS in the ICU. Overall hospital LOS across admissions was shorter for the same patients with complications, but the difference did not reach significance (10 vs 14.5 days, P = 0.33). Though a financial analysis was not performed in this study, these findings indicate that the use of the intra-aortic filter can possibly lead to a reduction in the cost of the whole cardiac surgical admission and lessen the financial burden to the institution.
Other novel emboli-capturing systems, such as CardioGard (Cardiogard Medical, Or Yehuda, Israel), that produce both a forward flow and a backward suction for extraction of solid and gaseous matter are also being studied and assessed for safety [11] . TriGuard, another aortic filter used during transcatheter aortic valve implantation, has been shown to be safe and efficacious in reducing cognitive decline at discharge and 30 days postoperatively [12] . A multicentre randomized study for this device failed to show any significant difference in different variables of adverse events including mortality, TIA, renal failure, ICU stays or hospitalizations. More data must be collected to show the efficacy of novel systems.
Limitations to our study include a retrospective observational design with its inherent flaws. It was carried out at a single institution with a limited number of surgeons. Despite thorough preoperative and intraoperative assessment of the aorta, some of the anatomic risk factors, including ascending and arch atheromas and calcifications, are not incorporated into the STS calculator. Specific patient demographics in this study may not be representative of the general population, though the use of the STS calculator to assess mortality risk allows us to standardize our patient population to those of the rest of the country. Propensity score matching is a valid statistical method of analysis, but it cannot circumvent the lack of randomization. To further examine the efficacy of the aortic filter, a multicentre randomized protocol should be created and followed.
In conclusion, the use of the EMBOL-X filter in high-risk cardiac surgical patients may decrease the overall complication rate and respiratory complications. In addition, patients who develop a complication after surgery may also have a shorter stay in the ICU, which could lead to a reduction in the cost for the procedure. Accordingly, we recommend the selective use of the EMBOL-X filter in high-risk cardiac surgical patients.
